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Abstract: Mucolipidosis type II (ML-II, I-cell disease) is a fatal inherited lysosomal storage disease caused by a deficiency of the
enzyme N-acetylglucosamine-1-phosphotransferase. A characteristic skeletal phenotype is one of the many clinical manifestations
of ML-II. Since the mechanisms underlying these skeletal defects in ML-II are not completely understood, we hypothesized that a
defect in osteogenic differentiation of ML-II bone marrow mesenchymal stem cells (BM-MSCs) might be responsible for this skeletal
phenotype. Here, we assessed and characterized the cellular phenotype of BM-MSCs from a ML-II patient before (BBMT) and after
BM transplantation (ABMT), and we compared the results with BM-MSCs from a carrier and a healthy donor. Morphologically, we
did not observe differences in ML-II BBMT and ABMT or carrier MSCs in terms of size or granularity. Osteogenic differentiation was
not markedly affected by disease or carrier status. Adipogenic differentiation was increased in BBMT ML-II MSCs, but chondrogenic
differentiation was decreased in both BBMT and ABMT ML-II MSCs. Immunophenotypically no significant differences were observed
between the samples. Interestingly, the proliferative capacity of BBMT and ABMT ML-II MSCs was increased in comparison to MSCs
from age-matched healthy donors. These data suggest that MSCs are not likely to cause the skeletal phenotype observed in ML-II, but
they may contribute to the pathogenesis of ML-II as a result of lysosomal storage-induced pathology.
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1. Introduction
Mucolipidosis II (ML-II, MIM# 252500 (McKusick,
2007)) is a rare, autosomal, recessively inherited lysosomal
storage disorder, characterized by coarse facial features,
progressive psychomotor retardation, severe skeletal
abnormalities, growth retardation, thick skin, gingival
hyperplasia, hernias, failure to thrive, and death within 5–8
years of age (McKusick, 2007). It is caused by a deficiency of
N-acetylglucosamine-1-phosphotransferase (EC 2.7.8.17),
which is normally located in the endoplasmic reticulum or
Golgi apparatus. The enzyme transfers GlcNAc-phosphate
to the oligosaccharide units of lysosomal enzyme
precursors (Kudo et al., 2006; Wang et al., 2018). The
resulting mannose 6-phosphate (M6P) moiety of these
hydrolases normally binds to specific receptors that direct
the enzymes to the lysosomes. However, in ML-II, these
enzymes are not trafficked properly to the lysosomes and
instead leak out of the cells, causing massive accumulation
of undigested substrates in lysosomes (Mazrier et al., 2003).

These lysosomes have been observed in skin fibroblasts
(Otomo et al., 2009), gingival fibroblasts (Koehne et
al., 2016), and mesenchymal stromal cells (Leroy et al.,
1971; Tondeur et al., 1971) as rough granular cytoplasmic
inclusions, hence the origin of the term ‘inclusion cell
(I-cell) disease’.
Although the molecular basis for this disorder is
unknown, evidence indicates that the genetic defect
results in an altered oligosaccharide side chain on the
I-cell acid hydrolases (Singh et al., 2017). As a result,
lysosomal hydrolases can be detected in serum, urine,
and cerebrospinal fluid.1 Heterozygote carriers have been
shown to have intermediate levels of phosphotransferase
activity. Enzyme replacement therapy (ERT) using a
recombinant enzyme, designed to be incorporated by the
M6P receptor and directed to lysosomes, is available for
some of the lysosomal storage diseases (Schiffmann et al.,
2000; Amalfitano et al., 2001; Schiffmann, 2010). However,
in the case of ML-II, ERT could not be developed, since
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the lysosomes display problems trafficking a multitude
of enzymes dependent on the M6P receptor pathway.
Extrinsic replacement of GlcNAc-phosphotransferase
is difficult because of its localization and hexameric
composition. Hickman and Neufeld (1972) showed
that ML-II fibroblasts could absorb lysosomal enzymes
released by normal cells, whereas normal cells could not
take up enzymes secreted by ML-II fibroblasts.
Hematopoietic stem cells (HSCs) are the source of all
mature blood cells and reside in the bone marrow. HSCs
have been shown to express and secrete a number of
lysosomal enzymes (Lund et al., 2014) and bone marrow
transplantation (BMT) has been shown successful in the
treatment of leukemias (Wayne et al., 2010), lymphomas
(Bhatt and Vose, 2014), anemias (Lucarelli et al., 2012), and
certain metabolic disorders (Wynn, 2011). Mesenchymal
stem cells (MSCs) are multipotent progenitors that are part
of the hematopoietic niche and coexist with HSCs in the
bone marrow (BM), but also participate in the regulation
of bone mass (Infante and Rodriguez, 2018). MSCs have
the ability to differentiate into various cell types, migrate
to sites of injury, secrete a wide range of hematopoietic
cytokines and growth factors, and have important immune
modulatory/immunosuppressive properties. In addition,
their ready availability and easy expansion makes them
promising candidates for the treatment of many diseases.
Since the mechanisms underlying the skeletal defects in
ML-II are not completely understood, we hypothesized that
the skeletal features of ML-II disease may be partly caused
by differentiation defects of MSCs and transplantation of
MSCs from healthy donors might be helpful in relieving
symptoms caused by the skeletal phenotype. Since
transplantation of BM involves coinfusion of both HSCs
and MSCs, this formed the basis for considering allogeneic
BMT for the treatment of ML-II.
Here, we isolated and characterized MSCs isolated
from the BM of a ML-II patient before and after BMT and
compared the cellular phenotype, based on morphology,
proliferation, differentiation, and immunophenotype,
with BM-MSCs from a healthy age-matched donor and a
ML-II carrier.
2. Materials and methods
2.1. Patient material
Use of human material was approved by the Hacettepe
University Institutional Ethics Committee (FON03/163). The ML-II patient was a 4-month-old boy with a
homozygous mutation in the GNPTAB gene, born to
consanguineous parents. The patient presented with a
course face, congestive heart failure, hepatosplenomegaly,
skeletal deformities, and developmental delay. Based
on significantly increased lysosomal enzyme levels of
alpha-mannosidase (5233 µmol/L/h), beta-mannosidase
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(5194 µmol/L/h), beta-hexosaminidase A (678 µmol/
l/h), and beta-hexosaminidase A+B (11350 µmol/L/h),
the patient was diagnosed with I-cell disease. At the age
of 8.5 months, the patient received 4.3 × 106/kg bone
marrow CD34+ cells from his HLA identical sibling after
myeloablative conditioning with busulfan (16 mg/kg)
and cyclophosphamide (200 mg/kg). Mesenchymal stem
cells (1 × 106 cell/kg) from the same donor were infused
to support hematopoiesis. Peripheral blood chimerism
analysis showed 95% donor engraftment at +1 month, 49%
at +2 month, and 39% at +3 month posttransplantation.
BM samples for MSC analysis were obtained before and
at 1 month after transplantation. The carrier used in the
study was the sister of the patient. She was 8 years old
at the time of bone marrow collection and the presence
of a heterozygous mutation in the GNPTAB gene was
molecularly confirmed. The carrier did not show any
specific signs of ML-II. A 1-year-old healthy donor was
selected to serve as the nonrelated healthy control. Since
this donor was healthy and there was no indication to
perform gene screening for a mutation in the GNPTAB
gene, this was omitted.
2.2. Isolation and culture of MSCs
Two milliliters of bone marrow from the ML-II patient,
a healthy donor, and a carrier were diluted with PBS and
mononuclear cells were isolated using Ficoll Hypaque
(1.077 g/L; Biochrom). Cells were cultured in expansion
medium consisting of Dulbecco’s modified Eagle’s mediumlow glucose (DMEM-LG, GIBCO) supplemented with 10%
fetal calf serum (FCS; GIBCO), 35.6% MCDB201 (Sigma),
and 1% antibiotics (penicillin 10,000 U/mL, streptomycin
10,000 µg/mL; Biochrom AG). Cells were incubated at 37
°C in 5% CO2 and the medium was changed every 3–4
days. Nonadherent cells were discarded. Analyses were
performed using passage 3 (P3) cells.
2.3. Differentiation assays
Adipogenic, osteogenic, and chondrogenic differentiation
tests were performed to assess the differentiation potential
of healthy, carrier, and ML-II BM-MSCs (Köse et al., 2018).
2.3.1. Adipogenic differentiation
MSCs were grown to full confluency on six-well plates and
exposed to adipogenic induction medium (DMEM-LG,
10% FCS, 1% penicillin/streptomycin (Biochrom), 1 µM
dexamethasone (Sigma), 60 µM indomethacin (Sigma),
0.5 mM isobutylmethyl-xanthine (IBMX; Sigma), and
5 µg/mL insulin (Sigma)) for 21 days. The medium was
replaced every 2–3 days. Oil Red O (Sigma-Aldrich)
staining was performed for morphologic examination.
Semiquantitative measurements were performed by
extracting the ORO dye and measuring the absorbance at
a wavelength of 492 nm (Tecan).
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2.3.2. Osteogenic differentiation
MSCs were cultured for 70% confluency and exposed
to osteogenic induction medium (DMEM-LG, 10%
FCS, 1% penicillin/streptomycin (Biochrom), 100
nM dexamethasone, 10 mM beta glycerophosphate
(Applichem), and 0.2 mM L-ascorbic acid (Sigma))
for 21 days. The medium was replaced every 2–3 days.
Cells were stained with Alizarin Red S (Sigma-Aldrich)
for morphologic analysis. Semiquantitative analysis of
calcium content was performed using a QuantiChrom
Calcium Assay Kit (DICA-500, Bioassay systems) and
measured at 620 nm.
2.3.3. Chondrogenic differentiation
To confirm the chondrogenic differentiation potential
of the MSCs, pellet culture was conducted. Cells were
added to 15-mL conical tubes (2 × 105 cells per tube)
and centrifuged to form pellets. After 24 h, the culture
medium was carefully replaced with serum-free
chondrogenic induction medium consisting of DMEMHG supplemented with 1% penicillin/streptomycin
(Biochrom), 10 ng/mL recombinant human TGF-β3
(Merck), 100 nM dexamethasone (Sigma), 0.1 mM
L-ascorbic acid (Fluka), 1 mM sodium pyruvate (Sigma),
and 1% ITS+ (Collaborative Biomedical Products) in
order not to disturb the three-dimensional structure of the
small pellets. The medium was changed every 2–3 days for
3 weeks. Quantification was performed using a Blyscan
Glycosaminoglycan Assay Kit (Biocolor Life Science) and
absorbance was measured at 656 nm.
2.4. Immunophenotype of MSCs
P3 MSCs were characterized with respect to the expression
of surface antigens. For flow cytometry, cells were
trypsinized to obtain a single cell suspension. Cells were
incubated for 15 min in the dark at room temperature
with 5 µL of fluorochrome-conjugated monoclonal
antibody (BD Pharmingen or e-Bioscience). Cells were
analyzed for mesenchymal (CD29, CD90, CD105, CD73,
CD44, CD49e, and CD146) and other cell surface markers
related to immune function or differentiation status of the
cells (HLA-DR, HLA-ABC, CD200, ALP, and CD271).
After incubation, cells were washed and 10,000 events
were recorded for each sample using a FACSARIA flow
cytometer (Becton Dickinson, USA). Data were analyzed
using BD FACSDiva Software v6.1.2.
2.5. Population doubling assay
P3 MSCs were seeded in a six-well plate at a concentration
of 3 × 104 cells/well and cultured with expansion medium.
Culture medium was replaced every 2 days. Cells were
harvested at 3, 5, 7, and 10 days. Viability and cell number
were assessed with Trypan blue dye (1:1, v:v).
2.6. Statistical analysis
Descriptive results were presented as mean ± SEM and
median (min–max). Normality of the distribution of

variables in every study group was evaluated by the
Shapiro–Wilk test and differences between study groups
(with nonparametric distribution) were assessed by
Wilcoxon’s test. P < 0.05 was considered statistically
significant.
3. Results
3.1. Morphology
BM-MSCs from all samples showed a spindle-shaped
fibroblastic appearance. Intracytoplasmic inclusions
were observed in ML-II BM-MSCs both before (BBMT)
and after BM transplantation (ABMT) (Figure 1).
Hematopoietic cells colocalized with P0 BBMT ML-II
BM-MSCs (Figures 1a and 1b), but not with ABMT BMMSCs or carrier and donor MSCs despite similar culture
conditions (Figure 1).
3.2. Differentiation capacity of MSCs
BM-MSCs from all sources differentiated into adipogenic,
osteoblastic, and chondrogenic lineages. Morphologic
analyses demonstrated that MSCs retained their ability
to form osteoblasts and adipocytes at P3 (Figure 2). The
semiquantitative assays for adipogenic, osteogenic, and
chondrogenic differentiation showed a better adipogenic
differentiation capacity of BBMT ML-II BM-MSCs than
ABMT ML-II, carrier ML-II, and donor BM-MSCs (Figure
2a). Conversely, GAG levels were decreased in both BBMT
and ABMT ML-II MSCs in comparison to MSC from an
age-matched normal control donor and the ML-II carrier.
The differentiation potential of BM-MSCs from the ML-II
carrier and the unrelated donor was similar.
3.3. Immunophenotype of MSCs
Immunophenotyping showed that MSCs from all groups
were brightly positive for CD105, CD44, CD73, CD49e,
and CD90 and dim positive for CD146, but negative for
HLA-DR, HLA-ABC, ALP, CD200, and CD271 surface
antigens (Table), confirming the MSC identity of our cells.
3.4. Proliferative capacity of MSCs
BM-MSC proliferation of the BBMT and ABMT, carrier,
and healthy donor samples was similar until day 3.
Thereafter, BBMT BM-MSCs showed increased speed of
proliferation in comparison to the other groups (Figure
3). This increase became more pronounced on the 9th and
10th days of the analyses compared to other groups and
especially healthy donor cells (P < 0.05) and BBMT BMMSCs (P < 0.05) (Figure 3).
4. Discussion
Mesenchymal stem cells are important components of
the BM niche and support maintenance of HSCs through
secretion of soluble factors and cell–cell contact (Infante
and Rodriguez, 2018). MSCs have been shown to give rise
to several different cellular lineages, including osteoblasts
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a

b

c

d

e

f

Figure 1. Microscopic analysis of the morphology of human (a, b) BBMT ML-II MSCs (20×, 40×, respectively), (c) ABMT ML-II MSCs
(20×), (d, e) carrier MSCs (20×, 40×, respectively), and (f) healthy donor MSCs (10×).

(Infante and Rodriguez, 2018). Since the pathophysiology
of the skeletal phenotype observed in ML-II has not yet
been elucidated, we hypothesized that the differentiation
and/or proliferative capacity of ML-II BM-MSCs might
be affected and be partially responsible for the bone
abnormalities of ML-II patients. Therefore, we compared
and characterized the capacities of ML-II patient BMMSCs before and after BMT with healthy donor and ML-II
carrier BM-MSCs.
ML-II disease is often called I-cell disease due to the
intracellular accumulation of membrane-bound vacuoles
in chondrocytes, osteoblasts, osteocytes, and stromal
fibroblasts of patients with ML-II (Leroy et al., 1971;
Pazzaglia et al., 1992; Poulopoulos et al., 2011). Phasecontrast microscopy of ML-II BBMT and ML-II ABMT
BM-MSCs showed accumulation of dense vacuoles or
inclusion bodies that are thought to be swollen lysosomes
filled with undigested substrates caused by the absence of
lysosomal acid hydrolases. Storage materials in lysosomes
are likely a mixture of various substrates, since ML-II
lysosomes may lack multiple lysosomal enzymes. The
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colocalization of hematopoietic cells with BBMT ML-II
MSCs suggests that they preserve their hematopoiesissupporting features.
Bone changes are a prominent feature of ML-II disease
and since the defect in skeletal tissues in ML-II could
be caused by abnormal differentiation of BM-MSCs,
we compared the differentiation capacity of ABMT,
BBMT, carrier, and donor BM-MSCs. While adipogenic
differentiation of ABMT and carrier MSCs was similar to
that of donor MSCs, BBMT BM-MSCs displayed a higher
adipogenic differentiation capacity. This may explain why
in certain metabolic and lysosomal storage diseases the fat
content of the bone marrow is increased (Tondeur et al.,
1982). Increased adipogenic differentiation is also often
associated or correlated with a decrease in osteogenic
differentiation (Moerman et al., 2004). For instance,
it has been observed in humans that when the number
of MSCs committed to the adipocyte lineage increases,
the number of cells committed to the osteoblast lineage
decreases (Maas et al., 2002; Moerman et al., 2004;
Pastores and Meere, 2005). Although we did not find such
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Figure 2. Semiquantitative analysis of adipogenic (a), osteogenic (b), and
chondrogenic cell differentiation (c) of human BM-MSCs obtained from MLII BBMT, ML-II ABMT, ML-II carrier, and donor BM.

a corresponding decrease in bone differentiation, others
have observed a severe reduction of trabecular bone
volume associated with an increased cortical porosity
in ML-II mice compared to control mice. Interestingly,
this phenotype appeared to be the consequence of an

unbalanced ratio between osteoblast and osteoclast
activities, where bone formation was severely reduced
and bone resorption strongly increased (Kollmann et al.,
2013). On the other hand, there was no difference in the
osteogenic differentiation of BM-MSCs obtained from a
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Table. Cell surface marker percentages of BM-MSCs.
Cell surface marker
percentages

ML-II BBMT MSC

ML-II ABMT MSC

ML-II Carrier MSC

Healthy donor MSC

CD44

99.6%

99.3%

99.3%

99.8%

CD73

99.0%

99.4%

99.3%

99.9%

CD105

76.1%

91.3%

84.2%

98.7%

CD146

31.1%

33.1%

16.3%

52.0%

HLA-DR

0.2%

0.1%

3.1%

0.0%

CD49e

99.0%

98.8%

97.7%

99.7%

HLA-ABC

0.5%

0.0%

3.3%

0.1%

CD90

99.6%

98.9%

99.7%

99.6%

ALP

0.0%

0.0%

0.0%

0.6%

CD200

2.3%

0.6%

5.2%

0.1%

CD271

0.0%

0.1%

0.0%

0.3%

Figure 3. Proliferation of human BBMT, ABMT ML-II, carrier,
and healthy donor BM-MSCs (*P < 0.05).

patient with Gaucher disease, another lysosomal storage
disease (Lecourt et al., 2012).
Another possible explanation for the defects in skeletal
tissues in ML-II patients could be impaired chondrogenic
differentiation of BM-MSCs. The differentiation capacity
of BM-MSCs from the carrier was similar to that of
healthy donor BM-MSCs, but both BBMT and ABMT
BM-MSCs displayed dramatically decreased GAG levels
after chondrogenic induction. Skeletal development and
homeostasis are coordinated processes that are controlled
by three main cell types: chondrocytes in the cartilage
and osteoblasts and osteoclasts in bone (Karsenty et al.,
2009). During puberty, longitudinal bone growth is mainly
regulated by chondrocyte proliferation, differentiation,
and matrix deposition, whereas matrix calcification is
controlled by the opposed and finely balanced activities
of osteoblasts, the bone-forming cells, and osteoclasts, the
bone-resorbing cells. Dysregulation of this balance may
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lead to many severe bone disorders, such as osteopetrosis
(Uckan et al., 2009) and osteoporosis (Karsenty et al.,
2009). Excessive activity of one of the proteases, cathepsin
K, plays a central role in the cartilage morphogenesis
defects and type II collagen accumulation observed in MLII zebrafish embryos (Flanagan-Steet et al., 2009; Petrey
et al., 2012) and human blood plasma (Tomatsu et al.,
2010). The findings also highlight the fact that activation
of secondary biochemical pathways is a common feature
of lysosomal diseases.
To better understand the pathology of the diseases and/
or to develop new treatment targets, further studies should
be performed, focusing on in vivo ML-II modeling and
assessing the defects at a molecular level. However, before
studies with ML-II models in vivo, in vitro immunogenic
and inflammatory properties of ML-II MSCs obtained
from more patients should be examined in detail. In a
study of aspartylglucosaminuria (AGU), a lysosomal
storage disease causing neuronal dysfunction and various
connective tissue signs, altered collagen and proteoglycan
gene expression in cell culture was observed. Reduced
mRNA levels of type I and III collagens correlated with the
low collagen synthesis in AGU fibroblast cultures (Maatta
et al., 1994).
We observed that the proliferative capacity of BBMT
and ABMT ML-II MSCs was higher than that of carrier
and donor cells. Information on the proliferative capacity
of fibroblasts or MSCs of this disease is not available in the
literature. However, it is known that gingival fibroblasts
of the patients show excessive proliferation (Nishimura
et al., 2002; Lee and O’Donnell, 2003). Complete loss of
cathepsin-L function resulted in the development of gingival
overgrowth in these patients (Nishimura et al., 2002). Also,
some have suggested that cathepsin D, an aspartic protease,
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acts as a cell-death mediator (Tardy et al., 2004a). Another
explanation might be the relative resistance of I-cell
apoptosis induced by cellular stress caused by differences
in activity and/or compartmentalization of cathepsins
(Terman et al., 2002). Also, TNF-induced cell death was
found to be strongly inhibited in I-cell fibroblasts (Tardy et
al., 2004b). Another reason for the high apoptosis in cells
may be the mitochondria. Mitochondria play key roles in
activating apoptosis in mammalian cells (Jeong and Seol,
2008). Mitochondrial dysfunctions in this disorder were
shown in human skin fibroblasts (Otomo et al., 2009).
However, the study results are limited due to fact that only
a single ML-II sample was used. In addition, the age of
the patient was very low. In order to prevent bias due to
age-related changes, results of the ML-II BM-MSCs were
compared to BM-MSCs obtained from a healthy donor of
similar age.
Allogeneic bone marrow transplantation provides longterm hematopoietic engraftment and is effective in selected
lysosomal and peroxisomal storage disorders. Clinical
correction of the disease phenotype is variable and based
on the organ systems involved, the age of the patient at the
time of transplant, and the nature of the metabolic defect.
MSCs have the potential to differentiate into cells of bone,
cartilage, tendon, muscle, and other adventitial tissues
and offer a potential for regenerative tissue therapy. Our
challenge is to understand the biology of BM-MSCs and
to determine a successful means of their therapeutic use in

the clinic. Here, we showed that osteogenic differentiation
of ML-II BM-MSCs was not severely affected, although
chondrogenic differentiation was somewhat decreased.
These differences are unlikely to have a severe effect on
the skeletal phenotype; therefore, the skeletal damage
observed in ML-II is probably caused by lysosomal storage
of multiple enzymes in highly proliferative tissues during
embryogenesis and fetal development may be causative.
Data from new patients should be used to confirm these
results. Lysosomal storage disorders, including ML-II,
are excellent candidates for gene therapy since they are
well-characterized single-gene disorders and the enzyme
expression is generally not subject to complex regulation
mechanisms. Although enzyme replacement in these
patients is conceptually impossible, isolated MSCs
could be genetically modified by lentiviral or CRISPR
methodologies to overexpress or correct the mutation in the
GNPTAB gene. In this way we could get better insight into
the precise role of missing gene activity in adipogenesis,
osteogenesis, and chondrogenesis and the development of
the pathology of the disease. Further studies are needed to
better understand the consequences of the genetic defects
and the resulting severe skeletal abnormalities observed in
ML-II patients.
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